PROCEPT BioRobotics (PRCT) Stock Looks Overvalued Against Its Sales Story
PROCEPT BioRobotics (PRCT) Stock Dropped, So What Is Driving Attention Now?
Truist Securities Maintains Hold on PROCEPT BioRobotics, Raises Price Target to $24
UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21
Leerink Partners Maintains Market Perform on PROCEPT BioRobotics, Raises Price Target to $22
PROCEPT BioRobotics Corporation Q3 2026 Earnings Call Summary
PROCEPT BioRobotics Corp (PRCT) (Q3 2026) Earnings Call Highlights: Revenue Grows 18% as Hydros ...
PROCEPT BioRobotics Q3 Earnings Call Highlights
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates
PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
PROCEPT BioRobotics Q3 2026 Earnings Call Transcript
PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $395.409M Est
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PROCEPT BioRobotics (PRCT) Stock May Be Fully Priced On Cash Flow Hopes
PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board Change
Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30
Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?
Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.